Poging GOUD - Vrij

How alarming Is Monkeypox Threat Perception?

BioSpectrum Asia

|

October 2024

As the world finally emerges from the grip of COVID-19, a new threat looms: Mpox (formerly known as Monkeypox).

- Ayesha Siddiqui

How alarming Is Monkeypox Threat Perception?

In August 2024, the World Health Organisation (WHO) declared Mpox a global health emergency due to the rising cases of the new strain, clade I Mpox in Africa and Sweden, underscoring the urgent need for coordinated global action to monitor and contain the virus. As of September 2024, 2082 confirmed Mpox cases were reported globally, marking the highest number of monthly cases globally since November 2022. Nearly 400 cases have been reported in Asia Pacific this year.How are Asia Pacific countries stepping up surveillance measures and preparing their healthcare systems to combat Mpox? And just how significant is the threat posed by this outbreak? Let’s explore.

Two years after the World Health Organization (WHO) declared a global health emergency over an Mpox outbreak, a deadlier strain, clade 1b, emerged in the Democratic Republic of the Congo (DRC) in September 2023. This came just months after the WHO had ended the 2022 global health emergency in May 2023. By August 2024, the new outbreak, largely concentrated in the DRC and its African neighbours, was declared a Public Health Emergency of International Concern (PHEIC), sparking concerns of a wider spread similar to the 2022 outbreak, which affected 122 countries.

There are two clades of Mpox: clade I and clade II. Endemic to Central Africa, clade 1 is the most deadly, causing a severe illness and – in past outbreaks – killing up to 10 per cent of those who become unwell. Clade II, on the other hand, which had spread globally in 2022, has a survival rate of over 99.9 per cent and is endemic to West Africa. Five countries in Africa (Burundi, DRC, Kenya, Rwanda and Uganda) and three countries outside of Africa (Sweden, Thailand, India) have reported clade Ib monkeypox virus (MPXV) as of September 22, 2024.

MEER VERHALEN VAN BioSpectrum Asia

BioSpectrum Asia

BioSpectrum Asia

Kyorin and Lunatus partner to launch Lasvic tablets in 9 Middle Eastern countries

Japan's Kyorin Pharmaceutical has entered into an exclusive distribution agreement with Lunatus Marketing & Consulting FZCO for Lasvic tablets (Lascufloxacin hydrochloride).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Biotium launches GlycoLiner Cell Surface Glycoprotein Labeling Kits

US-based Biotium, a leading innovator in fluorescent dyes and life science reagents, has announced the launch of GlycoLiner Cell Surface Glycoprotein Labeling Kits for rapid, selective, and covalent labeling of cell surface glycoproteins.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vaxxas appoints former Merck Global Vaccines President David Peacock as CEO

Australia-based Vaxxas has announced the appointment of global biopharmaceutical executive David Peacock as Chief Executive Officer (CEO) to lead the commercialisation of the company's proprietary high-density microarray patch (HD-MAP) vaccination technology.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Thermo Fisher partners with NVIDIA leveraging AI to advance scientific instrumentation

US-based Thermo Fisher Scientific Inc. has announced a strategic collaboration with NVIDIA to power artificial intelligence (AI)based solutions and laboratory automation at scale.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Bruker consolidates ownership of TOFWERK in expansion of mass spectrometry portfolio

Bruker Corporation has announced the acquisition of an additional 60 per cent ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker's ownership to 100 per cent.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Bioengineered tissue by Japan emerges as revolutionary treatment for secondary lymphedema

A research team led by Associate Professor Kosuke Kusamori from the Faculty of Pharmaceutical Sciences at Tokyo University of Science (TUS), Japan, is pioneering an innovative technique for lymphatic tissue engineering that could revolutionize the treatment of secondary lymphedema.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Chitose and Fujifilm Biosciences to drive global innovation and biopharma manufacturing

Japan-based Chitose Laboratory Corp. & Fujifilm Biosciences Inc. have announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Vibrant Therapeutics on-boards Dr Han Lee as Co-CEO

Vibrant Therapeutics, a clinical-stage biotechnology company based in China and US, has announced the appointment of Dr Han Lee as co-chief executive officer (CEO).

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

IIT-D and AIIMS develop swallowable microdevice for microbiome study

Researchers at the Indian Institute of Technology (IIT) Delhi, and All India Institute of Medical Sciences (AIIMS) have developed an ingestible device that can sample bacteria directly from the small intestine, opening a new window into the human gut microbiome.

time to read

1 min

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Ambitious research to develop multivalent vaccines against multiple deadly filoviruses

Scientists at the University of Oxford, in collaboration with partners, will spearhead the development of new vaccines that aim to provide comprehensive protection against multiple lethal filoviruses, including Ebola virus, Sudan virus, Bundibugyo virus, and Marburg virus.

time to read

1 min

BioSpectrum Asia Feb 2026

Listen

Translate

Share

-
+

Change font size